Effect of an angiotensin II type 1 receptor blocker on caveolin-1 expression in prostate cancer cells

Agnieszka Wanda Piastowska-Ciesielska, Marcin Kozłowski, Waldemar Wagner, Kamila Domińska, Tomasz Ochędalski

Abstract

Introduction: Caveolin-1, the major structural protein of caveolae, interacts directly with the AT1 receptor. The biological functions of caveolin-1 in cancer are compound, multifaceted, and depend on cell type, tumor grade and cancer stage. The AT1-R-caveolin complex in caveolae may coordinate angiotensin II (Ang II) induced signalling. The aim of this study was to determine the effect of the angiotensin II receptor type 1 blocker candesartan on caveolin expression in human metastatic prostate adenocarcinoma cells PC-3.

Material and methods: WST-1 and BrdU assays were used as indicators of cell viability and proliferation after angiotensin II and/or candesartan stimulation. Real-time RT-PCR and western blot were used to study the effect of Ang II and/or candesartan on the expression of Cav-1 and AT1-R in PC-3 cells.

Results: We found that the expression of caveolin-1 mRNA in the PC-3 cells treated with CV was significantly decreased in comparison with the control (2.9 ±0.17, 4.7 ±0.6, p < 0.05), whereas a higher caveolin-1 mRNA expression was observed in those after Ang II treatment (6.0 ±0.43, 4.7 ±0.6, p < 0.05). Protein analysis indicate that the expression of caveolin-1 protein in the PC-3 cells treated with candesartan was significantly decreased when compared with the control (0.69 ±0.05, 1.6 ±0.12, p < 0.05), whereas higher caveolin-1 protein expression was observed after Ang II treatment (2.5 ±0.20, 1.6 ±0.12, p < 0.05).

Conclusions: These results provide new information on the action of candesartan and may improve the knowledge about AT1 receptor inhibitors, which can be potentially useful in prostate cancer therapy.

Key words: caveolin-1, angiotensin II type 1 receptor, angiotensin II, candesartan, prostate cancer.

Introduction

Previous studies on caveolin-1 (Cav-1) in prostate cancer have shown that its expression and secretion are associated with the development of prostate cancer [1]. Caveolin-1 is one of the three members of the caveolin family of proteins [2]. It is an indispensable membrane protein of approximately 21-24 kDa, found primarily in plasma membrane caveolae, the non-clathrin coated vesicles important in endocytosis and signalling. Caveolae are known to accu-
mulate cholesterol, glycosphingolipids and signalling proteins. Although under some conditions Cav-1 may suppress tumourigenesis, it is mostly associated with cancers and contributes to malignant progression through various mechanisms [3, 4]. In addition to its role in caveolae formation, Cav-1 also functions in cellular signalling by sequestering receptors and intracellular signalling proteins within caveolae [2]. Specific proteins such as receptor tyrosine kinases, serine/threonine kinases, phospholipases, G protein-coupled receptors, and Src family kinases are located in lipid rafts and caveolar membranes, where they interact with Cav-1 [2, 4]. The molecular mechanisms of the initiation of Cav-1 expression in prostate cancer and other malignancies are not clear [4]. The Cav-1 and Cav-2 genes are located on human chromosome 7q31, a highly conserved region that encompasses a known fragile site whose deletion is associated with the loss of heterozygosity, while amplification has been reported in a variety of human cancers, including prostate cancer [5]. Over-expression of Cav-1 has been reported in various cancers, including colon, kidney, bladder, lung, pancreas and ovary cancers, and in some types of breast cancer [4]. The level of Cav-1 expression may depend on the tumour type and stage; for example, high Cav-1 levels were reported in late or advanced squamous cell carcinoma and in metastatic prostate cancer [4]. The relationship between Cav-1 over-expression in prostate cancer and an aggressive, clinically significant type of the disease has been found consistently in many studies [4].

Angiotensin II (Ang II), which is a major effector peptide of the renin-angiotensin system (RAS), is well known to be an important factor in hypertension [6, 7]. An involvement of the local RAS with autocrine-paracrine roles rather than the endocrine effect has recently been documented in relation to growth and differentiation in many organs [8, 9]. It has been reported that Ang II is involved in the development and invasion of some cancers, including breast, ovarian and pancreatic cancers [10-12]. Ang II activates the signal transduction of mitogen-activated protein kinase and signal transducers and angiogenesis in prostate cancer cells [8, 13]. Moreover, Ang II facilitates the secretion of some growth factors and cytokines from prostate stromal cells, resulting in cell proliferation in prostate cancer [8, 14]. Ang II exerts major regulatory actions via activation of the Gq/11 protein-coupled angiotensin II receptor type 1 (AT1-R) [9, 15]. In many tissues (including the prostate), activation of the AT1 receptor leads to cell growth and differentiation responses through downstream signalling molecules that include phospholipase C, protein kinase C (PKC), the Ras-Raf-MEK-ERK signalling pathway, and signal transducers and activators of transcription (STATs) [15, 16].

The aim of this study was to investigate the effect of Ang II and an AT1-R blocker (candesartan) on caveolin-1 expression in metastatic PC-3 prostate cancer cells.

Material and methods

Cell line and cell culture conditions

Metastatic prostate adenocarcinoma cells (PC-3) were obtained from ATCC and maintained in RPMI-1640 (Life Technologies, Corporation) with 10% fetal bovine serum (FBS) (Life Technologies, Corporation). The cells were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO2. Before each experiment, the PC-3 cells were serum-deprived and cultured in a phenol red-free medium for a period of 12 h. In all experiments the cells were exposed to angiotensin II (10 µM) (Sigma-Aldrich) and candesartan (10 µM) (Astra Zeneca) for 12 h and 24 h, or they were pre-treated with candesartan (10 µM) for 4 h and cultured in a medium in the presence of angiotensin (10 µM) for 12 h or 24 h. For WST-1 and BrdU assays the PC-3 cells were plated at a density of 4 × 105 cells/well in 96-well plates. For RNA or protein extraction, the cells were grown in 8 cm² culture dishes and at 60-70% confluence they were treated with Ang II or candesartan (CV) as described previously.

Cell viability assays

Cell viability was determined by a WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-benzene disulfonate) reagent (Roche Applied Science, Poland) according to the manufacturer’s instructions. WST-1 allows convenient assays using a tetrazolium salt which produces water-soluble formazan. To detect the effect of Ang II and candesartan on cell viability, PC-3 cells were plated in 96-well plates at a density of 4 × 103 cells/well and allowed to adhere overnight before the beginning of treatment.

The cells were exposed to Ang II with or without CV for 12 h to 24 h. Simultaneously the viability of non-treated, control cells was assessed. At the end of the exposure period, the medium was replaced with 100 µl of the (1 : 10 dilution) WST-1 in a fresh medium in each well and incubated for 2 h. Absorbance was measured on an ELISA plate reader (BioTeck) at 450 nm with reference at 655 nm. The effect of Ang II and CV was expressed as: (OD of treated cells/OD of non-treated cells) × 100. The analysis was performed in three independent experiments.

Cellular proliferation was measured using a colorimetric immunoassay based on bromodeoxyuridine (BrdU) incorporation into the cellular DNA, following the instructions recommended by the manufacturer (Roche Applied Science). The experimental design was parallel to those set for the WST-1 assay. The cells were incubated with BrdU labelling reagent for 4 h, followed by fixation in a FixDenat solution for 30 min at room temperature.
membranes were then blocked in 5% non-fat milk/Rad) and transferred to PVDF membranes. The lane was resolved in 12.5% gel using SDS-PAGE (Bio-tech). Protein extracts were mixed with the Laemmli buffer, heated for 1 min at 100°C. Next 30 µg protein per manufacturer’s protocol, using bovine serum albumin as a reference protein for the standard curve. The protein concentration was determined by the Bradford method (Bio-Rad) according to the manufacturer’s instructions. cDNA samples were diluted with sterile deionised water to a total volume of 100 µl and 2 µl was added to a PCR reaction. Real-time RT-PCR was performed using a LightCycler (Roche Diagnostics). We analysed the relative expression levels of caveolin-1 (Cav-1) and AT1-R genes. The levels were normalised to GAPDH and ACTB. The primers described in Table I were designed using Primer3 software (http://frodoww.mit.edu/). All analyses were performed using a LightCycler FastStartDNA Master SYBR Green I kit (Roche Diagnostics) according to the procedure provided by the producer.

Western blot analysis

Total protein extracts were isolated from cells using the RIPA protein extraction buffer, supplemented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich) and 1 mM PMSF (Sigma-Aldrich). The lysates were centrifuged at 14,000 x g and 4°C for 20 min, and the pellets were discarded. Protein concentration was determined by the Bradford method (Bio-Rad) according to the manufacturer’s protocol, using bovine serum albumin as a reference protein for the standard curve. The protein extracts were mixed with the Laemmli buffer, heated for 1 min at 100°C. Next 30 µg protein per lane was resolved in 12.5% gel using SDS-PAGE (Bio-Rad) and transferred to PVDF membranes. The membranes were then blocked in 5% non-fat milk/TBST or 5% BSA/TBST for 1 h at room temperature. After this time they were incubated overnight at 4°C with selected primary antibodies: anti-caveolin-1 (sc-894) and anti-AT1-R (sc-1173) (Santa Cruz Biotechnology Inc.). After the overnight incubation, the membranes were washed three times (3 × 15 min) with TBST and incubated for 1 h in a solution of secondary antibodies conjugated with alkaline phosphatase (Sigma-Aldrich). After the second incubation they were washed three times (3 × 15 min) in the TBST buffer. The colour reaction was induced using SIGMAFAST™ BCIP®/NBT (Sigma-Aldrich). Bands were visualised on the membranes. A densitometric analysis of protein levels was performed with ImageJ 1.34 s software (Wayne Rasband, National Institutes of Health, USA. http://rsb.info.nih.gov/ij/) and the results were expressed as optical density (OD). The results were normalised for glyceraldehyde-3-phosphate dehydrogenase (GAPDH (sc-59540)) (Santa Cruz Biotechnology Inc.).

Statistical analysis

WST-1 and BrdU: The experimental results are shown as the mean ± SE. Groups were compared using ANOVA followed by the Tukey post hoc test. Significance was defined as p < 0.05 (GraphPad Prism Software). The PCR array data were analysed by the ∆ΔCt method [17]. An average of housekeeping genes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin (ACTB) was used to obtain the ΔCt value for each gene of interest. The ∆ΔCt value for each gene was calculated as the difference between the ΔCt of the treated groups and that of the control. The fold-change for each gene was calculated by the 2−ΔΔCt method.

Results

Candesartan inhibits the growth of metastatic prostate adenocarcinoma cells

To determine whether the AT1 receptor (AT1-R) is expressed in metastatic prostate adenocarcinoma cells (PC-3), we analysed the AT1-R gene expression and protein level. As shown in Figures 1A and B, AT1-R was expressed in the PC-3 cells and its expression did not differ between the treated

Table I. List of primer sequences used in the study

| Gene   | Description                          | Primer sequences (5’→3’)                        | Product size [bp] |
|--------|--------------------------------------|-------------------------------------------------|-------------------|
| ATR-1  | Angiotensin II receptor, type 1      | ATTGCACCCAGGTGATCAA AAACCAAGCTGTTTTCCAAAT       | 168               |
| CAV-1  | Caveolin-1                           | AGTGCATACGGCGGTATCCCA TCTGCAAGTTGATGCGGACATTGC | 102               |
| GAPDH  | Glyceraldehyde-3-phosphate dehydrogenase | ACAGTCAACCCGATCTTACGT TACCAATCGTTCCTC          | 91                |
| ACTB   | β-Actin                              | ACCAATGGGACGACATGGGAA TGGCAGCCTTGATGCAGCTGA    | 192               |
untreated cells. To investigate the effect of Ang II on metastatic prostate adenocarcinoma cells, we used the angiotensin II receptor blocker candesartan (CV), which is a selective blocker for AT1-R. The results of the BrdU assay revealed that Ang II treatment significantly increased the number of PC-3 cells in comparison with the control conditions (126.4 ±7.13, p < 0.05), whereas higher caveolin-1 protein level was also noted in cells treated with candesartan and angiotensin (2.5 ±0.20, 1.6 ±0.12, p < 0.05). A lower caveolin-1 protein level was also noted in cells treated with both candesartan and angiotensin in comparison with the control (0.8 ±0.08, 1.6 ±0.12, p < 0.05).

Expression of caveolin in prostate adenocarcinoma cells

At first, we examined whether caveolin-1 mRNA and protein were expressed in PC-3 cells. The results of real-time reverse transcription PCR indicated that the expression of caveolin-1 mRNA in the PC-3 cells treated with CV was significantly decreased in comparison with the control (2.9 ±0.17, 4.7 ±0.6, p < 0.05), whereas a higher caveolin-1 mRNA expression was observed in those after Ang II treatment (6.0 ±0.43, 4.7 ±0.6, p < 0.05) (Figure 2 A). A decreased caveolin-1 mRNA level was also shown in cells having undergone candesartan and angiotensin treatment (2.7 ±0.39, 4.7 ±0.6, p < 0.05). Protein expression showed a similar pattern. The results shown in Figures 2 B and C indicate that the expression of caveolin-1 protein in the PC-3 cells treated with candesartan was significantly decreased when compared with the control (0.69 ±0.05, 1.6 ±0.12, p < 0.05), whereas higher caveolin-1 protein expression was observed after Ang II treatment (2.5 ±0.20, 1.6 ±0.12, p < 0.05). A lower caveolin-1 protein level was also noted in cells treated with both candesartan and angiotensin in comparison with the control (0.8 ±0.08, 1.6 ±0.12, p < 0.05).

Discussion

The strong evidence of the effects of Ang-II and candesartan (CV) on prostate cancer cells and tumour growth has been confirmed by many studies [8, 18-20]. However, our results show for the first time that the angiotensin II receptor type 1 (AT1-R) is involved in caveolin-1 (Cav-1) expression.

Figure 1. AT1-R expression in prostate cancer cells and inhibition of cell proliferation by candesartan in PC-3 cells. A – Total RNA from prostate adenocarcinoma cells was extracted and AT1 receptors were detected by real-time RT PCR. B – Representative Western blot with anti-AT1 receptor antibody. a – non-treated PC-3 cells, b – PC-3 cells exposed to angiotensin II (10 µM), c – PC-3 cells exposed to candesartan (10 µM), d – PC-3 cells pre-treated with candesartan and exposed to angiotensin II. C, D – The effect of Ang II and CV on cell proliferation and viability. Columns, mean of three different experiments; *p < 0.05). Control – non-treated cells, Ang II – the cells exposed to angiotensin II, CV – the cells exposed to candesartan, Ang II/CV – cells pre-treated with candesartan and exposed to angiotensin II.
The AT1 receptor is a non-palmitoylated G-protein-coupled receptor expressed in many cell types, including endothelial and epithelial cells that are co-immunoprecipitated with caveolin [21]. The AT1-R-caveolin complex in caveolae may coordinate Ang II induced signalling. Acting as a molecular chaperone, this protein is necessary for correct transport of AT1-R to the plasma membrane [21]. Cav-1, the major structural protein in caveolae, interacts directly with AT1-R, a subunit of Gq, Src family kinases and EGFR via a consensus motif (caveolin scaffolding domain) present in cytoplasmic domains of these signalling proteins [22]. Cav-1 has been shown to possess a double role in cancer and to act both as a tumour suppressor and a tumour promoter [1]. Evidence of a role of Cav-1 in cancer biology remains controversial even within a specific group of cancers, as Cav-1 expression varies among cancer subgroups [23]. Karam et al. have shown that Cav-1 over-expression in prostate cancer was associated with established features of aggressive tumours such as a higher Gleason grade and a pre-operative serum prostate-specific antigen (PSA) level [24]. The same group reported that Cav-1 expression was significantly associated with features of aggressive prostate cancer recurrence, such as rapid failure to respond to salvage local radiation therapy, and amplified possibility of developing early distant metastases. These results confirm a previous observation of Yang et al., who found a correlation between caveolin-1 expression and positive lymph node metastases as well as the Gleason grade of the cancer, indicating that caveolin-1 expression is associated with progression/metastasis of prostate cancer [25].

Ishizaka et al. presented an interaction between the AT1 receptor and caveolae in vascular smooth muscle cells [26]. It was the first report showing that Cav-1 expression was regulated by hormonal stimulation. Interestingly, they found that only Cav-1 mRNA, but not caveolin-2 or -3, was significantly regulated by Ang II [26]. They showed that Ang II stimulated upregulation of caveolin-1 mRNA, which confirmed our observation on metastatic prostate adenocarcinoma cells (PC-3). In contrast to our observation, they found that Ang II significantly reduced Cav-1 protein, but on the other hand [35S]methionine labelling showed that Ang II increased caveolin biosynthesis. These results indicate the influence of Ang II on increased caveolin turnover. The data also confirm the evidence relating the AT1 receptor to the caveolae, both structurally and functionally. Aung et al. reported in their study that a decrease in PC-3 cell motility and matrix degradation capability was associated with increased Cav-1 expression [1]. These results are in opposition to the well-documented increased aggressiveness associated with Cav-1 expression in prostate cancer [1, 25, 27]. It is possible that the caveolar and non-caveolar Cav-1 may play different roles in prostate cancer cells, and that the elevation of non-caveolar Cav-1 increases malignant progression [1]. Targeting Cav-1 to caveolae via other molecules such as PTRF prevents migration and matrix degradation [1]. Takaguri et al. concluded that caveolin-1 was involved in the vascular remodelling induced by Ang II [22]. Cav-1 plays a critical role in the key signalling step in which angiotensin II induces the transactivation of the epidermal growth factor.
receptor (EGFR), leading to the hypertrophy and migration of vascular smooth muscle cells. Gan et al. reported that the upregulation of EGFR was involved in prostate cancer progression, but also that an impaired endocytic downregulation of EGFR contributed to oncogenic phenotypes, such as metastasis [28]. Their results additionally suggest that the therapeutic targeting of ERK signalling may have undesirable outcomes (for example, augmenting EGFR-driven motility) [28].

In conclusion, our results have demonstrated that the angiotensin II receptor type 1 blocker candesartan plays a role in the regulation of caveolin expression at the mRNA and protein levels. The present study provides new information on the action of candesartan, and may improve our knowledge about AT1 receptor inhibitors, which can be potentially useful in prostate cancer therapy.

Acknowledgments

Grant Support: this work was supported by the
teaching staff and the Medical University of Lodz grant 502-03/0-078-
04/502-04-008 and Ministry of Science and High-
3er Education grant N404 1077 33.

References

1. Aung CS, Hill MM, Bastiani M, Parton RG, Parat MO. PTRF-
cavin-1 expression decreases the migration of PC3 prostate cancer cells: role of matrix metalloproteinase 9. Eur J Cell Biol 2011; 90: 136-42.
2. Bennett N, Hooper JD, Lee CS, Gobe GC. Androgen receptor and caveolin-1 in prostate cancer. IUBMB Life 2009; 61: 961-70.
3. Thompson TC. Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev 1998-1999;17: 439-42.
4. Thompson TC, Tahir SA, Li L, et al. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Pro-
static Dис 2010; 13: 6-11.
5. Timme TL, Goltsov A, Tahir S, et al. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Onco-
gene 2000; 19: 3256-65.
6. Piastowska-Ciesielska AW, Drobnik J, Zarzyńska J, Domiń-
ska K, Russell JA, Ochędalski T. Influence of myoccardial infar-
ton changes in the expression of angiotensin type 1 receptor in the rat prostate. Folia Histochem Cytobiol 2011; 49: 497-503.
7. Lubas A, Żelichowski G, Próchnicka A, Wiśniewska M, Sara-
cyn M, Warlıkowicz Z. Renal vascular response to angiotensin II inhibition in intensive antihypertensive treatment of essential hypertension. Arch Med Sci 2010; 6: 533-8.
8. Uemura H, Ishiguro H, Ishiguro Y, et al. Antiproliferative
the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics. Tumour Biol 2012; 33: 767-74.
9. Dominska K, Piastowska AW, Rebas E, Lachowicz-Ochę-
dalska A. The influence of peptides from the angiotensin fam-
ily on tyrosine kinase activity and cell viability in a human hormone-dependent prostate cancer line. Endokrynol Pol 2009; 60: 363-69.
10. Uemura H, Ishiguro H, Nagashima Y, et al. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther 2005; 4: 1699-709.
11. Dominska K, Piastowska-Ciesielska AW, Lachowicz-Ochę-
dalska A, Ochędalski T. Similarities and differences between effects of angiotensin III and angiotensin II on human prostate cancer cell migration and proliferation. Peptides 2012; 37: 200-06.
12. Bartnicki P, Majewska E, Wilk R, Baj Z, Rysz J. Captopril and
13. Uemura H, Ishiguro H, Nagashima Y, et al. Antiproliferative
activity of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics. Tumour Biol 2012; 33: 767-74.
14. Dominska K, Piastowska AW, Rebas E, Lachowicz-Ochę-
dalska A. The influence of peptides from the angiotensin fam-
ily on tyrosine kinase activity and cell viability in a human hormone-dependent prostate cancer line. Endokrynol Pol 2009; 60: 363-69.
15. Uemura H, Ishiguro H, Nagashima Y, et al. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther 2005; 4: 1699-709.
16. Dominska K, Piastowska-Ciesielska AW, Lachowicz-Ochę-
dalska A, Ochędalski T. Similarities and differences between effects of angiotensin III and angiotensin II on human prostate cancer cell migration and proliferation. Peptides 2012; 37: 200-06.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expres-
sion data using real-time quantitative PCR and the 2(-Delta
Delta C(T)) Method. Methods. Methods 2001; 25: 402-08.
18. Uemura H, Hasumi H, Ishiguro H, Teranishi I, Miyoshi Y, Kubota Y. Renin-angiotensin system is an important factor in
19. Yamagishi T, Uemura H, Nakaigawa N, Noguchi K, Kubota Y. Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer. J Urol 2005; 173: 441.
20. Bartnicki P, Majewska E, Wilk R, Baj Z, Rysz J. Captopril and

Arch Med Sci 4, August / 2013